TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

Subscribe today! Click here for our subscription offers.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Trib 30 stocks drop to four-month low
  2. PPG submits offer for French sealants, adhesives business unit
  3. Natural gas industry buys share of Super Bowl spotlight
  4. Wall Street closes January on down note; Dow sheds 251 points
  5. Consumer comes to the rescue as companies step back
  6. Phelan: Fuel-saving tips for winter driving
  7. Obama seeks $215M for precision medicine initiative
  8. Consol Energy posts $74M profit in fourth quarter
  9. BNY Mellon expands  role for treasury exec
  10. Kennametal plans plant closings, job cuts in fallout from oil and gas decline
  11. Subaru BRZ still needs upgrades